Biomarker Detection

Dr. Martin Kriebel
Molecular and Neurobiology

+49 7121 51530-810

E-Mail

anzeigen

AI-supported diagnosis of tumor-associated drug resistance

Late stage cancers have a high tendency to be resistant to chemotherapeutic agents. As a result, chemotherapy may not result in a positive response in many patients. The ability to reliably predict existing drug resistance could therefore enable personalized, alternative therapeutic decisions (e.g. adjuvant treatment in addition to chemotherapy) to mitigate drug resistance.

For this purpose, we are developing a new detection method that can be integrated into histological laboratory diagnostics, and in combination with an AI-based evaluation routine developed by project partners, allows quantitative determination of the activation status of cellular defence mechanisms. Multiple parameters of a central signalling pathway of the cellular stress response are addressed simultaneously. In coordination with a clinical partner who also provide sample material, we are currently working on development and validation of this new procedure.

Project

• IDOL - KI-basierte Diagnostik des Lungenkarzinoms zur Unterstützung personalisierter Therapieentscheidungen